Citations

Clear

1526 citation(s) found for "Sun, Yu".

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis
Zhang, Huimei , Chang, Na , Han, Tiantian , Qu, Guangbo , Liu, Haixia , Sun, Chenyu , Cheng, Ce , Zhou, Qin , Sun, Yehuan , Sun, Yehuan , Sun, Chenyu , Han, Tiantian, Ma, Shaodi

Mayo Clinic

Future Oncology | July 19, 2021 | Volume: 17 | Issue: 30 | Pages: 4027-4040

10.2217/fon-2021-0263 | PMID 34278818 Get It

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Miguel, Jesús F. San , Paiva, Bruno , Kumar, Shaji , Mateos, María‐Victoria , Usmani, Saad Z. , Cook, Gordon , Cavo, Michèle , Quach, Hang , Ukropec, Jon, Ramaswami, Priya, Pei, Huiling , Qi, Mia, Sun, Steven , Wang, Jianping , Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Rampelbergh, Rian Van , Kudva, Anupa, Kobos, Rachel, Qi, Ming , San-Miguel, Jesus , Paiva, Bruno , Kumar, Shaji K , Mateos, María-Victoria , Quach, Hang , Cook, Gordon , Usmani, Saad , Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Facon, Thierry T.F. , Touzeau, Cyrille , Jakubowiak, Andrzej , Bahlis, Nizar Jacques

Mayo Clinic

Blood | July 16, 2021 | Volume: 139 | Issue: 4 | Pages: 492-501

10.1182/blood.2020010439 | PMID 34269818 Get It

Abstract In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk
Li, Yafang , Xiao, Xiangjun , Byun, Jinyoung , Cheng, Chao , Bossé, Yohan , McKay, James , Lam, Stephen , Tardón, Adonina , Chen, Chu , Landi, Maria Teresa , Wichmann, Erich, Goodman, Gary, Field, John K. , Shete, Sanjay , Melander, Olle , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan P. , Purrington, Kristen S. , Yang, Ping , Bailey‐Wilson, Joan E. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Cheng, Chao , Wilson, Richard K , Field, John K , Tardón, Adonina , Bossé, Yohan , Grankvist, Kjell , Purrington, Kristen S , Byun, Jinyoung , Li, Jianrong , Albanes, Demetrius , Bojesen, Stig E. , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Christiani, David C. , Rennert, Gad , Arnold, Susanne M. , Marchand, Loı̈c Le , Brunnström, Hans , Liu, Geoffrey , Hung, Rayjean J. , Kiemeney, Lambertus A. , Shen, Hongbing , Sun, Ryan , Zienolddiny, Shanbeh , Teare, M. Dawn , Hong, Yun‐Chul , Davies, Michael P.A. , Lazarus, Philip J. , Schabath, Matthew B. , Han, Younghun , Pinney, Susan M. , Willey, James C. , Amos, Christopher I.

Mayo Clinic

No container title available | July 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-647012/v1 Get It

Abstract There is growing evidence showing that sex disparity in lung cancer risk cannot be fully explained by sex differences in smoking behavior, implying existence of genetic and molecular basis for sex disparity in lung cancer development. However, the information about sex dimorphism in lung cancer risk is quite limited despite the great success in lung cancer association studies. By adopting a stringent two-stage analysis strategy, we performed a genome-wide gene-sex interaction analysis using genotype from a lung cancer cohort including ~ 47,000 individuals with European ancestry. Three low-frequency variants (minor allele frequency < 0.05), rs17662871 (OR=0.71, p=4.29x10-8); rs79942605 (OR=2.17, p=2.81x10-8); and rs208908 (OR=0.70, p=4.54x10-8), were identified with different risk effect of lung cancer between men and women. Further eQTL and functional annotation analysis suggested rs208908 affect lung cancer risk through differential regulation of CXADR (Coxsackie Virus And Adenovirus Receptor) gene expression in lung tissues between men and women. Our study is one of the first studies to provide novel insights about the genetic and molecular basis for sex disparity in lung cancer development.
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
Vonderheide, Robert H. , Kraynyak, Kimberly A. , Shields, Anthony F. , McRee, Autumn J. , Johnson, Jennifer M. , Sun, Weijing , Pawlicki, Jan M. , Sylvester, Albert J. , McMullan, Trevor, Samuels, Robert J., Kim, Joseph , Boyer, Jean , Morrow, Matthew P. , Humeau, Laurent, Skolnik, Jeffrey , Kraynyak, Kimberly A , Chintakuntlawar, Ashish V. , Samuels, Robert, Weiner, David B

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 6, 2021 | Volume: 9 | Issue: 7 | Pages: e003019

10.1136/jitc-2021-003019 | PMID 34230114 Get It

Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. Methods A phase 1 clinical trial was conducted in adult patients with no evidence of disease following definitive surgery and standard therapy, who were at high risk of relapse. Plasmid DNA encoding one of two hTERT variants (INO-1400 or INO-1401) with or without plasmid DNA encoding interleukin 12 (IL-12) (INO-9012) was delivered intramuscularly concurrent with the application of the CELLECTRA constant-current electroporation device 4 times across 12 weeks. Safety assessments and immune monitoring against native (germline, non-mutated, non-plasmid matched) hTERT antigen were performed. The largest cohort of patients enrolled had pancreatic cancer, allowing for additional targeted assessments for this tumor type. Results Of the 93 enrolled patients who received at least one dose, 88 had at least one adverse event; the majority were grade 1 or 2, related to injection site. At 18 months, 54.8% (51/93) patients were disease-free, with median disease-free survival (DFS) not reached by end of study. For patients with pancreatic cancer, the median DFS was 9 months, with 41.4% of these patients remaining disease-free at 18 months. hTERT immunotherapy induced a de novo cellular immune response or enhanced pre-existing cellular responses to native hTERT in 96% (88/92) of patients with various cancer types. Treatment with INO-1400/INO-1401±INO-9012 drove hTERT-specific IFN-γ production, generated hTERT-specific CD4+ and CD8+ T cells expressing the activation marker CD38, and induced hTERT-specific activated CD8 +CTLs as defined by cells expressing perforin and granzymes. The addition of plasmid IL-12 adjuvant elicited higher magnitudes of cellular responses including IFN-γ production, activated CD4+ and CD8+ T cells, and activated CD8+CTLs. In a subset analysis of pancreatic cancer patients, the presence of immunotherapy-induced activated CD8+ T cells expressing PD-1, granzymes and perforin correlated with survival. Conclusions Plasmid DNA-encoded hTERT/IL-12 DNA immunotherapy was well-tolerated, immune responses were noted across all tumor types, and a specific CD8+ phenotype increased by the immunotherapy was significantly correlated with survival in patients with pancreatic cancer.
Abstract 047: Transgenic troponin T in Zebrafish recapitulates a Unique type of Cardiomyopathy
Sun, Xiaojing , Liu, Weibin , He, Bin , Xu, Xiaolei

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 113 | Issue: suppl_1 | Pages: No page available

10.1161/res.113.suppl_1.a047 Get It

Background: Cardiomyopathy-like phenotype has been recently reported in adult zebrafish stressed by either anemia or doxorubicin. However, it still remains unclear whether gene-based manipulation in this emerging animal model can faithfully recapitulate cardiomyopathy phenotypes in mammals. Here, we aim to address this question by generating the first transgenic model for cardiomyopathy in zebrafish. Results: We generated a panel of three transgenic fish lines, including Tg(cmlc2:Tnnt2) that overexpress wild type Tnnt2 in the whole heart, Tg(cmlc2:Tnnt2c) that drive a C-terminal amino acid truncated Tnnt2 (Tnnt2C) in the whole heart, and Tg(vmhc:Tnnt2c) that drives Tnnt2c expression only in the ventricle. Upon overexpression of the Tnnt2C, but not the full-length control, in the heart caused reduced ventricular size but enlarged atrium. A same morphological phenotype was noted in Tg(vmhc:Tnnt2c). At the cellular level, we found significantly reduced size of cardiomyocyte and increased cell proliferation. The morphological remodeling is accompanied by hallmarks of cardiomyopathy including reduced cardiac function and myofibril disarray. Conclusion: Transgenic overexpression of Tnnt2C in zebrafish faithfully recapitulates unique cardiomyopathy phenotypes noted in both human patients harboring the similar mutation and mice transgenic models, underscoring zebrafish as a conserved vertebrate model for cardiomyopathy. Our study further suggested that the dysfunction of Tnnt2C in ventricle is primarily responsible for cardiac phenotypes, while the enlarged atrium is a consequence of a defective ventricle.
Abstract 222: Valsartan at a Sub-therapeutic Dose Ameliorates Myocardial Autophagy Overactivated in Renovascular Hypertension (RVH)
Zhang, Xin , Li, Zilun , Crane, John A., Lerman, Lilach O. , Pawar, Aditya S. , Eirin, Alfonso , Lerman, Amir

Mayo Clinic

Hypertension | July 3, 2021 | Volume: 60 | Issue: suppl_1 | Pages: No page available

10.1161/hyp.60.suppl_1.a222 Get It

Objective: Excessive autophagy (degradation of intracellular structures) characterizes cardiomyocyte injury in hypertensive heart disease. The effect of Angiotensin II receptor blocker Valsartan on RVH-induced myocardial autophagy remains unexplored. Method: Twenty-one domestic pigs (50-60 Kg) were randomized into 3 groups: RVH, RVH+Valsartan, and Control (n=7 each), and observed for 10 wks. Valsartan (320mg/d PO) was administered for 4 wks starting at 6 wks of RVH. After 10 wks, myocardial fibrosis was examined by trichrome staining, and inflammation by M1 macrophage (M1 Ø, CD163+/iNOS+) staining and TNF-α expression (immunoblotting). Autophagy was examined for Atg 12-Atg 5, Beclin-1 and its inhibitor mTOR. Result: At 6 wks, MAP was higher in both RVH and RVH+Valsartan compared to Control (147.6 ±14.0 and 139.1±11.2 vs. 105.9±11.4 mmHg, respectively, P<0.05). At 10 wks, Valsartan did not decrease MAP compared to RVH (P=0.31), Both Beclin-1 and Atg 12-Atg 15 expressions that were elevated in RVH (P<0.05 vs. Control), indicating increased autophagy, were restored by Valsartan (Figure). Valsartan restored a compensatory increase in mTOR expression in RVH, and ameliorated myocardial fibrosis, M1 Ø, and TNF-α expression (Figure). Conclusion: Valsartan decreased myocardial autophagy, fibrosis and inflammation in pigs with RVH, independent of effective blood pressure control. Valsartan has novel pleiotropic effects on turnover of cellular structures in RVH-induced myocardial damage.
Abstract P212: Haploinsufficiency of Target of Rapamycin Attenuates Different Forms of Cardiomyopathies in Adult Zebrafish
Sun, Xiaojing , Huang, Wei , Hoage, Tiffany, Redfield, Margaret M. , Kushwaha, Sudhir S. , Sivasubbu, Sridhar , Ding, Yonghe , Lin, Xueying , Ekker, Stephen C. , Xu, Xiaolei

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 109 | Issue: suppl_1 | Pages: No page available

10.1161/res.109.suppl_1.ap212 Get It

In contrast to the wide application of zebrafish embryos in developmental genetic studies, the value of an adult zebrafish to dissect signaling pathways in human diseases such as cardiomyopathy remains largely elusive. Previously, we have established anemic tr265/tr265 fish as the first adult zebrafish model of cardiomyopathy. Here, we generate the second adult zebrafish cardiomyopathy model induced by injection of a single bolus of doxorubicin (DOX). Despite their different pathogenesis, cardiac enlargement induced by either anemia or DOX can be effectively attenuated by inhibition of target of rapamycin (TOR) signaling via rapamycin treatment. However, along the progression of both models, we have also detected dynamic TOR activity and distinct effects of TOR signaling inhibition at different stages of pathogenesis. To assess the long term effects of TOR haploinsufficiency, we utilized a zebrafish target of rapamycin (ztor) mutant that was identified from a mutagenesis screen. We show that sustained TOR inhibition in ztor/+ improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the anti-hypertrophy, anti-apoptosis, and pro-autophagy function of TOR signaling inhibition. Together, our results prove adult zebrafish as a novel vertebrate model for human cardiomyopathies and provide genetic evidences for a cardioprotective function of TOR signaling inhibition in different forms of cardiomyopathies.
Abstract 16514: Magnetic Resonance Imaging-Detected Carotid Plaque Characteristics Predict Systemic Cardiovascular Outcomes in Patients With Clinically Established Atherosclerosis in the AIH-HIGH Study
Zhao, Xue‐Qiao, Balu, Niranjan , Neradilek, Moni B. , Isquith, Daniel , Cantón, Gádor , Crouse, John R., Anderson, Todd J. , Polissar, Nayak L. , Yuan, Chun , Sun, Jie , Zhao, Xue-Qiao, Yamada, Kiyofumi , Huston, John , O’Brien, Kevin D. , Hippe, Daniel S. , Hatsukami, Thomas S

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.16514 Get It

Background: Although vulnerable plaques are considered the pathological substrate for acute cardiovascular events, the pursuit of imaging surrogate markers for systemic atherothrombotic risk is currently focused on plaque burden. The prognostic value of vulnerable plaque characteristics as novel markers for systemic cardiovascular outcomes remains elusive. Advances in magnetic resonance imaging (MRI) have enabled characterization of the vulnerable carotid plaque. In a prospective study, we tested whether MRI-detected carotid plaque characteristics predict subsequent cardiovascular events. Methods: As part of an event-driven clinical trial, subjects with clinically established atherosclerotic disease were recruited. A multi-sequence protocol was used to measure the volumes of calcification and necrotic core (NC), and to identify the presence of intraplaque hemorrhage (IPH) and thin/ruptured fibrous cap (FC) using published criteria. The primary endpoint included fatal and non-fatal myocardial infarction or ischemic stroke, hospitalization for acute coronary syndrome, and symptom-driven revascularization. Cox regression analysis was used to present results as hazard ratio (HR) with 95% confidence interval (CI). Results: Of 232 subjects recruited, 214 (92.2%) with diagnostic image quality constituted the study population (mean age: 61±9 years; male: 82%; statin use: 94%). Calcification, NC, IPH, and thin/ruptured FC were detected in 48%, 52%, 8% and 14% of subjects, respectively. During a median follow-up of 35.1 months, 18 (8.4%) subjects reached the primary endpoint. MRI-detected plaque characteristics associated with the primary endpoint included larger NC (HR per 1 standard deviation increase in volume [1-SD]: 1.43 [1.16, 1.75], p<0.001), thin/ruptured FC (HR: 4.31 [1.67, 11.12], p=0.003), and marginally IPH (HR: 3.00 [0.99, 9.13], p=0.053). Although calcium deposition is traditionally pursued as a marker for atherosclerosis, subjects with larger calcification (HR per 1-SD: 0.60 [0.26, 1.41], p=0.20) did not show increased risk. Conclusions: Vulnerable plaque characteristics are prevalent in carotid arteries of patients with established atherosclerosis and are predictive of systemic cardiovascular outcomes.
Abstract 17289: Incidence of Cardiomyopathy and Mortality in Patients With Cobalt and Chromium Metal Hip Arthroplasty
Ponamgi, Shiva , Sharma, Sunita , Sun, Philip Philip, Yogeswaran, Vidushei, Padmanabhan, Deepak , El‐Harasis, Majd , Hodge, David O. , Slusser, Joshua P. , Abdel, Matthew, Sun, Philip Y. , Sun, Philip , DeSimone, Christopher V. , Wyles, Cody C. , Sun, Philip Philip, Asirvatham, Samuel J.

Mayo Clinic

Circulation | July 2, 2021 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.17289 Get It

Introduction: One million patients around the world have had total hip arthorplasty with 35% of them having metal-on-metal implants. Although there have been some case reports of cobalt cardiotoxicity from arthroprosthetic cobaltism resulting in dilated cardiomyopathy, incidence of cardiomyopathy and mortality in these patients is unknown. Objective: We therefore sought to determine the incidence of new onset cardiomyopathy (EF <40%) and associated mortality, in patients with metal hip arthroplasty. Methods: We retrospectively examined the records of the patients form our institutional total hip arthroplasty registry (Metal on Metal: MoM, Metal on Polyethylene: MoP, Ceramic on Ceramic: CoC and Ceramic on Polyethylne: CoP). Among 122 patients with baseline and follow up echocardiograms, cobalt and chromium levels were available in 12 patients, none of which developed incident cardiomyopathy. Results: The mean age of the population with metal group (MoM and MoP) was 53 years, predominantly males. During the follow up period of 10 years, the cumulative incidence (KM curve probabilities) of low EF <=40% in our study population was 14% in metal group as compared to 5% in non-metal group (CoC and CoP), (p value 0.51). At 15 years of follow up, among 122 patients, there were16 deaths in the metal group (81) and only 2 deaths in the non-metal group (41) (p value 0.15). Conclusions: In conclusion, although the incidence of cardiomyopathy as well as mortality is low in patients with metal hip arthroplasty and not significantly, further studies maybe needed to assess its effect on diastolic dysfunction.